Treatment with monoclonal antibodies, especially rituximab, is more and more frequent and questions the interest of radiotherapy in limited stages of diffuse B-cell large cell and follicular non-Hodgkin's lymphomas. From a review of literature, it appears that radiotherapy is of interest in bulky disease, patients with incomplete metabolic response, elderly patients receiving short chemotherapy and those with recurrence after exclusive chemotherapy. Finally, this article gives recommendations on available techniques of radiotherapy and doses to be delivered.
Keywords: Diffuse B-cell lymphomas; Follicular lymphomas; Lymphomes B diffuse à grandes cellules; Lymphomes folliculaires; Lymphomes non hodgkiniens; Non-Hodgkin's lymphomas; Radiotherapy; Radiothérapie; Rituximab.
Copyright © 2016 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.